智通财经网·2025-08-27 10:53Core Insights - Fosun International reported a total revenue of 87.283 billion RMB for the six months ending June 30, 2025, with a net profit attributable to shareholders of 661 million RMB and basic earnings per share of 0.08 RMB [1][2] - The group's overseas business revenue reached 46.67 billion RMB, accounting for 53% of total revenue, reflecting a 6.6 percentage point increase compared to the same period in 2024 [1] - The company invested 3.6 billion RMB in technology and innovation during the reporting period, with a strong focus on medical research and development [1] - The insurance business, primarily driven by Fosun Portugal Insurance, showed robust revenue growth, contributing to a 3.3% year-on-year increase in the affluent business segment [1] - The revenue from the four major subsidiaries (Fosun Pharma, Yuyuan, Fosun Portugal Insurance, and Fosun Tourism) totaled 63.61 billion RMB, representing 73% of the group's total revenue [2] - The group's operational profit for the reporting period was 3.15 billion RMB, reflecting a year-on-year decline of 9.3%, primarily due to decreased profits in the leisure business segment [2]